newsfilter
← Earnings
Earnings Releases·

Coya Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss widened to $10.6 million for the three months ended September 30, 2026, compared to $2.1 million in the prior year period, driven by an $8.6 million increase in R&D expenses and a decline in collaboration revenue to $0.2 million from $3.6 million.
  • Cash and cash equivalents decreased to $35.8 million as of September 30, 2026, from $46.8 million at year-end 2025, while financing activities generated $10.7 million in net cash primarily through the sale of common stock.
  • The Phase 2/3 ALSTARS trial for COYA 302 has completed enrollment of 137 participants, with topline data anticipated in early Q2 2027; current reserves are sufficient to fund operations through the second half of 2027.
  • Management plans to initiate an open-label extension of the ALSTARS trial and a new Phase 2 study for COYA 302 in FTD in 2027, with additional mechanistic and biomarker data expected between Q4 2026 and Q1 2027.
Company
COYA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology